Hirotsu Bio Science utilizes a unique biodiagnostic technology that employs nematodes to detect trace odors in urine associated with various cancers, facilitating early diagnosis. This approach addresses the critical need for non-invasive cancer screening methods, enhancing patient outcomes through timely intervention.
Funding
$554.4M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Current methods for cancer screening often involve invasive procedures or have limitations in detecting early-stage cancers. There is a need for a non-invasive, accurate, and convenient screening method to improve early cancer detection rates.
Solution
Hirotsu Bio Science offers N-NOSE, a cancer screening service that utilizes nematodes to detect cancer biomarkers in urine samples. This method leverages the natural ability of nematodes to identify specific odor compounds associated with various cancers. By analyzing the movement of nematodes in response to urine samples, the test can identify the presence of cancer at an early stage. This non-invasive approach provides a convenient and accessible option for individuals seeking proactive cancer screening.
Target Audience
The primary target audience includes individuals seeking early cancer detection, healthcare providers looking for non-invasive screening tools, and corporations aiming to provide employee health benefits.
Features
- Utilizes nematodes to detect cancer-specific odor compounds in urine.
- Detects various cancer types through a single urine sample.
- Provides a non-invasive and convenient cancer screening method.
- Offers early-stage cancer detection capabilities.
- Results are available through designated testing facilities.